Good Morning,
Risk-tolerant investors may be seen as impatient by some. I prefer to say they’re opportunistic.
By that I mean they realize that letting the game come to you doesn’t matter unless you understand where the game is being played.
And that means looking for opportunities in sectors that are flying below the radar of many retail investors. These are stocks that don’t appear on lists of the most popular ones to buy. They aren’t large-cap stocks, and they don’t pay dividends.
Many are penny stocks.
But this creates, there’s that word again, opportunity. The chance to get in on stocks when they are undervalued and ride the stock price growth to substantial returns.
One of the areas that is beginning to heat up is the field of gene editing. Gene editing started with the human genome project in the late 1990s.
The benefit of mapping the human genome is that as scientists understand how genes work, the easier it will be to use technology to create cures that can deal with underlying problems created by problematic genes.
The next step is applying solutions to the information we have. Those solutions bring the hope that the world may finally achieve a goal of curing diseases like cancer and diabetes among others.
Many investment professionals will say that hope is not a strategy. But this is one time when you could disagree. Because while investing in these stocks is not without risk, they do offer real hope.
That hope is worth investing in if you have the right disposition and the ability to put some of your capital at risk.
Because if that hope turns into something more, it could make early investors very rich.
View the 7 Gene Editing Stocks with Game-Changing Potential
Laycee Kluin
MarketBeat
Today's Bonus Offer
Man who Predicted "End of Cash" Issues New Warning for September 20th (Ad)
In 2016, former banking VP Teeka Tiwari issued this warning: "A ban on cash is coming sooner than you think…and when it does, it will strip you bare of any privacy. The government will be able to peer into your most intimate financial dealings."
Click here to see the details and learn how to prepare.
This message is a paid advertisement sent on behalf of a third-party advertiser of MarketBeat. Why did I receive this email?
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com or leave us a voicemail at (844) 978-6257.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2023 American Consumer News, LLC dba MarketBeat.
326 E 8th St #105, Sioux Falls, SD 57103. United States.
No comments:
Post a Comment